Purpose: is to compare the success rate of Ex-PRESS implantation vs deep sclerotomy (DS) in patients with primary open-angle glaucoma (POAG). Patients and methods:This is a randomized prospective interventional comparative study between Ex-PRESS and DS maneuvers in patients with POAG. The study included 47patients (50 eyes) with POAG. The patients were divided into two groups. Group 1 included 25 patients (25 eyes) who underwent Ex-PRESS device implantation. Group 2 included 22 patients (25 eyes) who underwent DS. All included patients underwent a thorough ophthalmic examination. At the end of the 1 st year postoperatively, best corrected visual acuity (BCVA) [logMAR], intraocular pressure (IOP), number of anti-glaucoma medications in use were obtained. Results: In group 1, complete success rate was 76%, qualified success rate was 20% and failure rate 4% occurred in 1 eye of patients which needed explantation of the device and another glaucoma filtering surgery due to device-corneal touch. Meanwhile in group 2, complete success rate was36% and qualified success rate was 64% without any recorded failure in this group (Both Ps<0.01) in both groups. Conclusion: favorable effects on IOP and the need for IOPlowering medications in both Ex-PRESS and DS groups. However, in DS group, higher preoperative IOP is associated with increased failure rate necessitating more postoperative IOP adjustments than Ex-PRESS group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.